Passage Bio : Announces 2022 Research and Clinical Development Goals to Advance Robust CNS Pipeline - Form 8-K

Passage Bio Announces 2022 Research and Clinical Development Goals to Advance Robust CNS Pipeline




-


... | January 10, 2022

Related Keywords

University Of Pennsylvania ,Pennsylvania ,United States ,Princeton ,Philadelphia ,Gwen Fisher ,Stuart Henderson ,Bruce Goldsmith ,Exchange Commission ,Key Anticipated Company ,Clinical Development Goals To Advance Robust ,University Of Pennsylvania Gene Therapy Program ,Gene Therapy Program At Penn ,Passage Bio Inc ,Nasdaq ,Passage Bio Announces ,Clinical Development Goals ,Advance Robust ,Investigational New Drug ,Princeton West Innovation Campus ,Gene Therapy Program ,Passage Bio ,Anticipated Company Highlights ,Frontotemporal Dementia ,Granulin Mutations ,Krabbe Disease ,Charcot Marie Tooth Type ,Private Securities Litigation Reform Act ,Risk Factors ,Bio Investors ,Bio Media ,Nc Stock Exchange ,News ,Information ,Press Release ,Massage ,Ohio ,Nnounces ,022 ,Research ,End ,Linical ,Development ,Goals ,O ,Advance ,Obust ,Ns Pasg Us7027121000 ,